Finerenone in asian patients with diabetic kidney disease: evaluating the evidence for “better efficacy”

Clicks: 9
ID: 325454
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #28 of 129 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 129 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Diabetic kidney disease (DKD) has emerged as the primary driver of kidney failure across the Asia-Pacific region. Thus, therapeutic interventions capable of effectively slowing the progression of chronic kidney disease (CKD) and reducing concomitant cardiovascular risk are of critical strategic importance. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (nsMRA) approved for the treatment of DKD, exerts cardiorenal protective effects by selectively inhibiting the overactivation of the mineralocorticoid receptor (MR)—a key mediator of pathological inflammatory and fibrotic processes underlying renal and cardiac injury. A consistent finding across major clinical trials, including FIDELIO-DKD, FIGARO-DKD, and the pooled FIDELITY analysis, is the ‘potentially enhanced’ (based on post-hoc subgroup analyses) therapeutic efficacy of finerenone in Asian, predominantly Chinese, patient populations. This review synthesizes emerging evidence indicating a distinct, potentially superior therapeutic response (based on available subgroup analyses) in Asian cohorts compared to global populations, alongside potential genetic and environmental factors contributing to this phenomenon. Additionally, we address the associated safety profile of hyperkalemia in Asian patients. We contend that this risk is manageable through structured monitoring and should not preclude clinicians from utilizing this high-impact therapy. Ultimately, this review positions finerenone as a crucial and effective intervention for Asian patients with high cardiorenal risk, provided that potassium homeostasis is proactively managed.
Reference Key
openalex_W7203825067 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Siqian Gong, Linong Ji
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag279
URL
https://doi.org/10.1093/ckj/sfag279
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.